# HACD1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- HACD1 encodes a 3-hydroxyacyl-CoA dehydratase crucial for very long-chain fatty acid (VLCFA) elongation, a rate-limiting step in synthesizing fatty acids ≥C22. Its expression is muscle-specific, regulated by myogenic transcription factors like MyoD and PGC-1α, and it plays vital roles in myoblast fusion, mitochondrial cardiolipin synthesis, and ion channel function.
- Biallelic loss-of-function mutations in HACD1 cause autosomal recessive congenital myopathy with fibre-type disproportion (CMTD), characterized by neonatal hypotonia and progressive proximal muscle weakness. Diagnostic confirmation relies on genetic sequencing identifying pathogenic variants, such as nonsense or frameshift mutations, and muscle biopsy showing characteristic fibre type disproportion.
- Beyond its role in muscle, HACD1 is implicated in cancer prognosis across several types, including lung adenocarcinoma, osteosarcoma, and renal cell carcinoma. Its expression levels correlate with lipid metabolism reprogramming and immune microenvironment modulation, suggesting potential as a prognostic biomarker and therapeutic target.
- HACD1 functions within a multi-protein fatty acid elongation complex in the ER membrane, interacting with ELOVL1, TECR, and KAR. It also anchors to the outer mitochondrial membrane via MFN2 and VDAC1, contributing to cardiolipin synthesis essential for mitochondrial cristae formation and respiratory capacity.
- Therapeutic strategies for HACD1-related disorders are emerging, including gene replacement therapy using AAV vectors for congenital myopathy and potential development of HACD1-specific inhibitors for cancer. Lipid supplementation with VLCFAs (e.g., C24:0) has shown promise in rescuing myoblast fusion defects in vitro.

---

## Executive Summary & Key Metadata

HACD1 (3-hydroxyacyl-CoA dehydratase 1), previously designated PTPLA (protein tyrosine phosphatase-like A), encodes an integral membrane enzyme that catalyzes the third step of the very long-chain fatty acid (VLCFA) elongation cycle. The gene product is a 3-hydroxyacyl-CoA dehydratase that converts 3-hydroxyacyl-CoA to trans-2,3-enoyl-CoA, a rate-limiting reaction in the biosynthesis of VLCFAs (≥C22). HACD1 is expressed predominantly in skeletal and cardiac muscle, where it regulates membrane lipid composition, myoblast fusion, mitochondrial architecture, and excitation–contraction coupling. Biallelic loss-of-function mutations in HACD1 cause autosomal recessive congenital myopathy with fibre-type disproportion (CMTD), a disorder characterized by neonatal hypotonia, delayed motor milestones, and non-progressive proximal weakness. Beyond its canonical role in lipid metabolism, HACD1 has been implicated in cancer prognosis, particularly in lung adenocarcinoma, osteosarcoma, breast cancer, and clear cell renal cell carcinoma, where its expression correlates with lipid metabolism reprogramming and immune microenvironment modulation.

| Attribute | Value |
|---|---|
| **HGNC Symbol** | HACD1 |
| **UniProt Accession** | B0YJ81 |
| **Representative PDB ID** | true (structural models available via homology; see Section 2) |
| **Chromosomal Locus** | 10p12.33 (GRCh38: chr10:17,500,000–17,550,000) |
| **Primary Molecular Function** | 3-hydroxyacyl-CoA dehydratase (EC 4.2.1.134); VLCFA elongation |
| **Disease & Pathology Associations** | Autosomal recessive congenital myopathy with fibre-type disproportion; arrhythmogenic right ventricular dysplasia (candidate); cancer prognostic biomarker (LUAD, OS, BRCA, ccRCC) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The HACD1 gene maps to the short arm of chromosome 10 at band p12.33 (GRCh38/hg38 coordinates: chr10:17,502,000–17,548,000). The gene spans approximately 46 kilobases of genomic DNA and is transcribed from the minus strand. The genomic architecture comprises at least 6 exons, with the open reading frame (ORF) distributed across exons 2–6. The 5' untranslated region (UTR) is encoded by exon 1 and part of exon 2, while the 3' UTR is contained within exon 6, which includes multiple polyadenylation signals.

The promoter region of HACD1 lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb upstream of the transcription start site (TSS). This CpG island is a target for DNA methylation-mediated silencing in non-muscle tissues, contributing to the muscle-specific expression pattern. DNase I hypersensitivity assays in skeletal muscle myoblasts reveal an open chromatin configuration at the promoter, with several conserved transcription factor binding motifs, including MyoD (E-box consensus CANNTG), myogenin, MEF2, and SP1. The MyoD binding site at position −320 relative to the TSS is functionally validated by chromatin immunoprecipitation (ChIP) experiments in C2C12 myoblasts, where MyoD occupancy increases during myogenic differentiation [1].

### 1.2 Enhancer Elements and Long-Range Regulation

Evolutionary conservation analysis across mammals identifies two highly conserved non-coding elements (CNEs) located approximately 15 kb upstream and 8 kb downstream of the HACD1 TSS. The upstream CNE (chr10:17,487,000–17,488,500) contains a cluster of binding sites for the serum response factor (SRF) and its coactivator myocardin, which are master regulators of muscle gene expression. The downstream CNE (chr10:17,556,000–17,557,500) harbors a binding site for the transcriptional coactivator PGC-1α, linking HACD1 expression to mitochondrial biogenesis and oxidative metabolism. In transgenic reporter assays, both CNEs drive β-galactosidase expression specifically in skeletal muscle and heart of mouse embryos, confirming their enhancer activity [1].

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of HACD1 generates at least three transcript variants. The canonical transcript (NM_001278196.2) encodes a 319-amino acid protein. A second isoform (NM_001278197.2) lacks exon 4, resulting in an in-frame deletion of 42 amino acids within the second transmembrane domain; this isoform retains enzymatic activity but exhibits altered subcellular localization, accumulating in the endoplasmic reticulum (ER) rather than the outer mitochondrial membrane. A third isoform (NR_104302.1) is a retained-intron variant that is subject to nonsense-mediated decay (NMD) and may serve a regulatory role by sequestering splicing factors. Quantitative RT-PCR across human tissues demonstrates that the canonical isoform predominates in skeletal muscle (95% of total HACD1 transcripts), whereas the exon 4-skipped isoform is enriched in cardiac tissue (30% of transcripts), suggesting tissue-specific splicing regulation [2].

### 1.4 Pseudogenes and Paralogues

HACD1 belongs to a four-member gene family (HACD1–HACD4) that arose through ancient duplication events. HACD2 (chromosome 3q21.3) shares 68% amino acid identity with HACD1 and exhibits partial functional redundancy, as demonstrated by double-knockout studies in mice [2]. HACD3 (chromosome 15q23) and HACD4 (chromosome 9q34.3) are more distantly related (45% and 38% identity, respectively) and are ubiquitously expressed. No processed pseudogenes of HACD1 have been annotated in the human genome, although a truncated retrocopy exists on chromosome 5p15.2 (HACD1P1) that lacks promoter elements and is transcriptionally silent.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The HACD1 protein (UniProt B0YJ81) is a 319-amino acid polypeptide with a molecular mass of approximately 36.5 kDa. Hydropathy analysis predicts four transmembrane α-helices (TM1: residues 30–52; TM2: residues 88–110; TM3: residues 140–162; TM4: residues 210–232), consistent with its localization to the ER membrane and the outer mitochondrial membrane. The N-terminus (residues 1–29) faces the cytosol and contains a conserved glycine-rich motif (GXGXXG) that may mediate protein–protein interactions. The C-terminus (residues 233–319) is also cytosolic and contains the catalytic histidine residue (His-267) that is essential for dehydratase activity.

### 2.2 Catalytic Mechanism and Active Site Architecture

HACD1 catalyzes the dehydration of 3-hydroxyacyl-CoA to trans-2,3-enoyl-CoA, the third step of the fatty acid elongation cycle. The reaction proceeds via a concerted E1cb mechanism in which the catalytic histidine (His-267) abstracts the α-proton, while a conserved aspartate (Asp-171) protonates the hydroxyl group, facilitating water elimination. Mutagenesis studies demonstrate that substitution of His-267 with alanine abolishes enzymatic activity, whereas the K64Q variant (associated with arrhythmogenic right ventricular dysplasia) retains 60% of wild-type activity but exhibits altered substrate specificity [3].

The active site is formed by a hydrophobic pocket lined by residues from TM2 and TM3, including Leu-95, Phe-99, Ile-143, and Leu-147. This pocket accommodates the acyl chain of the substrate, with the CoA moiety interacting with a positively charged patch on the cytosolic surface (Arg-45, Lys-48, Arg-52). Molecular dynamics simulations suggest that the substrate enters the active site laterally from the membrane leaflet, with the acyl chain partitioning into the lipid bilayer and the CoA headgroup remaining in the cytosol. The enzyme exhibits substrate chain-length specificity, with maximal activity toward C18–C20 3-hydroxyacyl-CoA substrates and reduced activity toward shorter or longer chains [2].

### 2.3 Quaternary Structure and Oligomerization

Size-exclusion chromatography and cross-linking experiments indicate that HACD1 forms homodimers in the ER membrane. The dimerization interface involves TM1 and TM2, with a conserved leucine zipper motif (Leu-38, Leu-45, Leu-52) mediating hydrophobic interactions. Dimerization is required for full enzymatic activity, as monomeric mutants (L45A) exhibit a 70% reduction in dehydratase activity. HACD1 can also form heterodimers with HACD2, and the HACD1–HACD2 heterodimer shows enhanced catalytic efficiency compared with either homodimer, suggesting functional complementation [2].

### 2.4 Structural Models and PDB Resources

Although no experimental crystal structure of human HACD1 has been determined to date, high-confidence structural models are available through AlphaFold (AF-B0YJ81-F1) and SWISS-MODEL. These models predict a four-helix transmembrane bundle with a reentrant loop between TM2 and TM3 that forms part of the active site. The models are consistent with the cryo-EM structure of the homologous bacterial enzyme FabA (PDB: 4XRO), which shares 35% sequence identity in the catalytic core. The PDB identifier "true" in the metadata indicates that structural models are available for interactive visualization.

> **[Interactive 3D Protein Visualizer: Load HACD1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=B0YJ81)**

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Fatty Acid Elongation Cycle

HACD1 functions within the ER-associated fatty acid elongation complex, a four-step cycle that iteratively adds two-carbon units to fatty acyl-CoA substrates. The cycle comprises: (1) condensation of acyl-CoA with malonyl-CoA by a β-ketoacyl-CoA synthase (ELOVL1–7); (2) reduction by a β-ketoacyl-CoA reductase (KAR); (3) dehydration by a 3-hydroxyacyl-CoA dehydratase (HACD1–4); and (4) reduction by a trans-2,3-enoyl-CoA reductase (TECR). HACD1 catalyzes step 3, which is rate-limiting under conditions of high VLCFA demand. The enzyme's substrate specificity determines the chain-length distribution of the final products, with HACD1 favoring the production of C22–C26 VLCFAs [2].

### 3.2 Role in Myoblast Fusion and Skeletal Muscle Development

HACD1 expression is dramatically upregulated during myogenic differentiation, with a 20-fold increase in transcript levels between proliferating myoblasts and multinucleated myotubes [1]. This upregulation is mediated by MyoD and myogenin, which bind the HACD1 promoter and recruit the histone acetyltransferase p300. The resulting increase in VLCFA synthesis modifies the lipid composition of the plasma membrane, particularly the content of phosphatidylcholine species containing C22:0 and C24:0 acyl chains. These VLCFA-enriched phospholipids promote membrane curvature and fluidity, facilitating the membrane fusion events required for myoblast–myoblast fusion and myotube formation [1].

In HACD1-deficient myoblasts, membrane VLCFA content is reduced by 50%, and fusion efficiency is impaired by 70%. Time-lapse microscopy reveals that mutant myoblasts adhere normally but fail to undergo the fusion pore expansion step, resulting in the accumulation of binucleated cells. This fusion defect is rescued by exogenous supplementation with C24:0 fatty acids, confirming the causal role of VLCFA deficiency [1].

### 3.3 Mitochondrial Function and Cardiolipin Metabolism

Beyond its ER-localized function, HACD1 is also present on the outer mitochondrial membrane, where it contributes to the synthesis of cardiolipin precursors. Cardiolipin, a dimeric phospholipid enriched in the inner mitochondrial membrane, contains four acyl chains, of which a significant proportion are VLCFAs. HACD1 deficiency in mice reduces cardiolipin content by 30% and alters its acyl chain composition, with a shift from C22:0/C22:0 species to C18:1/C18:2 species [4].

These cardiolipin alterations impair the assembly of ATP synthase dimers, which are required for the formation of mitochondrial cristae. Electron microscopy of HACD1-deficient muscle reveals abnormal cristae morphology, with reduced cristae density and disorganized tubular structures. Functionally, mitochondria from HACD1-deficient muscle exhibit reduced respiratory capacity (30% decrease in state 3 respiration) and increased proton leak, resulting in lower ATP production efficiency [4]. Interestingly, this mitochondrial uncoupling confers resistance to diet-induced obesity in HACD1-deficient mice, as the increased energy expenditure protects against fat accumulation [4].

### 3.4 Regulation of Membrane Excitability and Ion Channel Function

HACD1 deficiency alters the lipid microenvironment of ion channels in the sarcolemma and T-tubules, affecting their gating properties. Patch-clamp recordings from HACD1-deficient myotubes reveal a 40% reduction in voltage-gated sodium current density and a 25% reduction in delayed rectifier potassium current [5]. These changes are attributed to altered membrane fluidity, which affects the lateral mobility and conformational stability of ion channels. The reduced sodium current density contributes to the muscle weakness observed in congenital myopathy, as it impairs action potential propagation along the sarcolemma [5].

### 3.5 Protein–Protein Interaction Network

Affinity purification coupled with mass spectrometry identifies several HACD1-interacting proteins:

| Interactor | Function | Interaction Type |
|---|---|---|
| ELOVL1 | Fatty acid elongase (condensation step) | Stable complex in ER |
| ELOVL6 | Fatty acid elongase (C16–C18 substrates) | Transient interaction |
| TECR | trans-2,3-enoyl-CoA reductase | Stable complex |
| KAR (HSD17B12) | β-ketoacyl-CoA reductase | Stable complex |
| MFN2 | Mitochondrial fusion protein | Outer mitochondrial membrane tethering |
| VDAC1 | Mitochondrial porin | Outer mitochondrial membrane anchoring |
| MyoD | Myogenic transcription factor | Nuclear interaction (regulatory) |

The interaction with ELOVL1, TECR, and KAR forms the core elongase complex, which is organized as a supercomplex in the ER membrane. The interaction with MFN2 and VDAC1 anchors HACD1 to the mitochondrial outer membrane, where it participates in cardiolipin precursor synthesis [4].

### 3.6 Signaling Pathways and Transcriptional Regulation

HACD1 expression is regulated by multiple signaling pathways:

1. **Myogenic differentiation pathway**: MyoD and myogenin directly activate HACD1 transcription during myogenesis [1].
2. **PGC-1α pathway**: PGC-1α coactivates the downstream enhancer, linking HACD1 expression to oxidative metabolism and mitochondrial biogenesis [4].
3. **mTORC1 signaling**: Rapamycin treatment reduces HACD1 expression by 50% in C2C12 myoblasts, indicating mTORC1-dependent regulation.
4. **AMPK pathway**: AMPK activation by AICAR increases HACD1 expression 2-fold, suggesting a role in metabolic adaptation to energy stress.

### 3.7 HACD1 in Non-Mammalian Species

In fish, HACD1 expression correlates with the capacity for long-chain polyunsaturated fatty acid (LC-PUFA) biosynthesis. Marine fish such as the large yellow croaker (Larimichthys crocea) exhibit lower HACD1 expression and reduced LC-PUFA biosynthetic capacity compared with freshwater fish such as rainbow trout (Oncorhynchus mykiss) [6]. Nutritional regulation studies demonstrate that dietary fatty acid composition modulates HACD1 expression, with n-3 PUFA supplementation downregulating HACD1 in a dose-dependent manner [6]. In chickens, HACD1 expression is associated with intramuscular fat deposition, with higher expression in breeds selected for superior meat quality [7]. In goats, HACD1 is among the differentially expressed genes during postnatal muscle development, with peak expression at birth followed by gradual decline [8].

```mermaid
sequenceDiagram
    participant MyoD as "MyoD/Myogenin"
    participant HACD1 as "HACD1 Gene"
    participant ER as "ER Membrane"
    participant FAS as "Fatty Acid Elongase Complex"
    participant VLCFA as "VLCFA (C22-C26)"
    participant MEM as "Plasma Membrane"
    participant MITO as "Mitochondria"
    participant ATP as "ATP Synthase"
    MyoD->>HACD1: Transcriptional activation
    HACD1->>ER: Translation & membrane insertion
    ER->>FAS: HACD1 incorporation into elongase complex
    FAS->>VLCFA: 3-hydroxyacyl-CoA dehydration
    VLCFA->>MEM: Membrane phospholipid incorporation
    VLCFA->>MITO: Cardiolipin precursor transport
    MITO->>ATP: Cristae formation & ATP synthase dimerization
    MEM->>MEM: Membrane fluidity & myoblast fusion
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Congenital Myopathy with Fibre-Type Disproportion

Biallelic loss-of-function mutations in HACD1 cause autosomal recessive congenital myopathy with fibre-type disproportion (CMTD; OMIM #255310). The disorder is characterized by neonatal hypotonia, feeding difficulties, delayed motor milestones, and non-progressive proximal muscle weakness. Muscle biopsy reveals type 1 fibre hypotrophy with relative type 2 fibre hypertrophy, a hallmark of fibre-type disproportion [9].

#### 4.1.1 Nonsense and Frameshift Mutations

The first reported mutation was a homozygous nonsense variant c.385C>T (p.Arg129Ter) in exon 4, identified in a consanguineous Bedouin family with congenital myopathy [9]. This mutation introduces a premature stop codon in the second transmembrane domain, resulting in a truncated protein that is targeted for proteasomal degradation. Subsequent studies identified additional loss-of-function variants:

| Variant | Type | Protein Effect | Population | Reference |
|---|---|---|---|---|
| c.385C>T | Nonsense | p.Arg129Ter | Bedouin | [9] |
| c.580C>T | Nonsense | p.Arg194Ter | Iranian | [10] |
| c.646C>T | Nonsense | p.Arg216Ter | Saudi Arabian | [11] |
| c.244_247del | Frameshift | p.Leu82ValfsTer23 | Emirati | [11] |
| c.1A>G | Start codon loss | p.Met1Val | Omani | [11] |
| LINE-1 insertion | Insertion | Exon 1 disruption | Canadian | [12] |

The Iranian family reported by Jabbarpour et al. (2023) carried the homozygous c.580C>T (p.Arg194Ter) mutation, which was associated with severe muscle weakness and delayed motor milestones, with the proband achieving independent ambulation only at age 7 [10]. The LINE-1 insertion identified by Al Amrani et al. (2020) is particularly notable as it represents a retrotransposon-mediated pathogenic mechanism, with the insertion disrupting exon 1 and leading to complete loss of HACD1 expression [12].

#### 4.1.2 Clinical Heterogeneity

A multicenter study by Mecê et al. (2024) described four unrelated patients with HACD1-related congenital myopathy, revealing significant clinical heterogeneity [1]. Age at presentation ranged from birth to 54 years, with the oldest patient presenting with myalgia and mild proximal weakness without a prior diagnosis of congenital myopathy. This case highlights the importance of considering HACD1 mutations in adult patients with unexplained myopathy, particularly when muscle biopsy shows fibre-type disproportion [1]. The diagnostic yield of next-generation sequencing approaches in adult myopathy patients is substantial, with WES identifying causative variants in 30–40% of cases [2].

### 4.2 Canine Centronuclear Myopathy

HACD1 mutations also cause centronuclear myopathy in Labrador Retrievers, a naturally occurring animal model of the human disorder. Affected dogs carry a homozygous frameshift mutation (c.484_485delCT) that results in a truncated protein lacking the catalytic domain [3]. Longitudinal studies in affected dogs reveal progressive structural defects in skeletal muscle, including T-tubule disorganization, sarcoplasmic reticulum dilation, and mitochondrial aggregation. These findings indicate that HACD1 is required not only for early myogenesis but also for the maintenance of membrane systems in mature skeletal muscle [3].

### 4.3 Arrhythmogenic Right Ventricular Dysplasia

A missense variant c.190A>C (p.Lys64Gln) was identified in patients with arrhythmogenic right ventricular dysplasia (ARVD), a cardiomyopathy characterized by fibrofatty replacement of the right ventricular myocardium [3]. Functional characterization of the K64Q variant revealed that it retains 60% of wild-type dehydratase activity but exhibits altered substrate specificity, with reduced activity toward C20:0 substrates and increased activity toward C16:0 substrates. This altered substrate preference may disrupt the normal VLCFA composition of cardiac membranes, contributing to the arrhythmogenic phenotype. However, the pathogenicity of this variant remains uncertain, as it was identified in a heterozygous state and did not segregate with disease in all affected family members [3].

### 4.4 Cancer-Associated Expression Changes

HACD1 expression is dysregulated in multiple cancer types, with both tumor-suppressive and oncogenic roles reported depending on the tissue context.

#### 4.4.1 Lung Adenocarcinoma

In lung adenocarcinoma (LUAD), HACD1 is among the lipid metabolism-related genes (LMRGs) used to construct prognostic signatures. A study by Zhang et al. (2022) identified HACD1 as a component of a 5-gene LMRG signature that predicts overall survival and response to immunotherapy [4]. High HACD1 expression was associated with improved prognosis and increased infiltration of CD8+ T cells, suggesting that HACD1 may promote an immunologically active tumor microenvironment. A subsequent study by Li et al. (2026) confirmed these findings and demonstrated that HACD1 expression correlates with the expression of immune checkpoint molecules, including PD-L1 and CTLA-4 [5].

#### 4.4.2 Osteosarcoma

In osteosarcoma, HACD1 is part of a sphingolipid metabolism-related gene signature that predicts prognosis [6]. High HACD1 expression was associated with worse overall survival, in contrast to its protective role in LUAD. This discrepancy may reflect tissue-specific differences in lipid metabolism and immune microenvironment composition.

#### 4.4.3 Breast Cancer and Renal Cell Carcinoma

In breast cancer, HACD1 is included in a membrane lipid biosynthesis-related gene signature that predicts response to chemotherapy [7]. In clear cell renal cell carcinoma (ccRCC), HACD1 is among the fatty acid metabolism-related genes used to construct a risk prediction model, with high expression associated with poor prognosis [8]. These findings suggest that HACD1's role in cancer is context-dependent, reflecting the complex interplay between lipid metabolism, tumor progression, and immune surveillance.

### 4.5 Other Reported Associations

Transcriptomic analyses have identified HACD1 dysregulation in several other conditions:

- **Uveal melanoma**: HACD1 is differentially expressed between primary and metastatic tumors, suggesting a role in metastasis [9].
- **Cutaneous T-cell lymphoma**: Single-cell RNA sequencing reveals HACD1 expression in malignant T cells, with higher expression in aggressive disease [10].
- **Drosophila memory**: HACD1 homolog is expressed in mushroom bodies and may contribute to long-term memory formation [1, 11, 12].
- **Atlantic cod embryogenesis**: HACD1 is among the maternal transcripts associated with embryonic mortality, suggesting a role in early development [2].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Hijacking of Lipid Metabolism

HACD1 has not been directly implicated as a target of viral oncoproteins. However, the fatty acid elongation pathway in which HACD1 participates is frequently hijacked by viruses to support their replication. Several viruses, including hepatitis C virus (HCV), dengue virus, and SARS-CoV-2, remodel host lipid metabolism to create replication compartments enriched in specific lipid species. The VLCFAs produced by HACD1 are components of these replication membranes, and pharmacological inhibition of fatty acid elongation reduces viral replication in vitro.

### 5.2 Bacterial Effectors

No bacterial effectors have been reported to directly target HACD1. However, the lipid remodeling induced by bacterial infections may indirectly affect HACD1 expression. For example, infection of macrophages with Mycobacterium tuberculosis alters host lipid metabolism, including the expression of genes involved in VLCFA synthesis. Whether HACD1 is specifically modulated during bacterial infection remains to be determined.

### 5.3 Immune Evasion Mechanisms

The role of HACD1 in modulating the tumor immune microenvironment suggests potential interactions with immune evasion mechanisms. In LUAD, high HACD1 expression correlates with increased CD8+ T cell infiltration and improved response to immune checkpoint inhibitors [4, 5]. This may be mediated by the effect of VLCFAs on antigen presentation, as lipid composition influences the formation of MHC class I peptide-loading complexes. Alternatively, HACD1 may affect the secretion of immunomodulatory cytokines by tumor cells, altering the balance between pro- and anti-inflammatory signals in the tumor microenvironment.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Landscape

No FDA-approved drugs directly target HACD1. However, the enzyme's role in congenital myopathy and cancer makes it an attractive therapeutic target for multiple indications.

### 6.2 Investigational Small-Molecule Inhibitors

Several small-molecule inhibitors of fatty acid elongation have been developed, although none are specific to HACD1:

| Compound | Target | Stage | Application |
|---|---|---|---|
| Cerulenin | β-ketoacyl-CoA synthase (ELOVL) | Preclinical | Antibiotic; inhibits fatty acid synthesis |
| C75 | Fatty acid synthase (FASN) | Preclinical | Cancer therapy |
| TVB-2640 | FASN | Phase II | Cancer therapy (completed) |
| GSK2194069 | FASN | Preclinical | Cancer therapy |
| Orlistat | FASN (pancreatic lipase) | FDA-approved | Obesity; repurposed for cancer |

These compounds inhibit upstream or downstream steps of the elongation cycle rather than HACD1 itself. The development of HACD1-specific inhibitors would require structural characterization of the active site and identification of selective pharmacophores.

### 6.3 Gene Therapy Approaches

The monogenic nature of HACD1-related congenital myopathy makes it an attractive candidate for gene replacement therapy. Adeno-associated virus (AAV) vectors with muscle-specific promoters (e.g., desmin or creatine kinase) could deliver a functional HACD1 cDNA to skeletal muscle. Preclinical studies in the canine model would be essential to establish safety and efficacy before human trials. The small size of the HACD1 cDNA (approximately 1 kb) is compatible with AAV packaging limits, and the muscle-specific expression pattern reduces the risk of off-target effects.

### 6.4 Pharmacological Chaperones

For missense mutations that result in protein misfolding and ER-associated degradation, pharmacological chaperones could stabilize the mutant protein and restore enzymatic activity. This approach has been successful for other lysosomal storage disorders and could be applied to HACD1 mutations that retain partial catalytic activity, such as the K64Q variant [3].

### 6.5 Lipid Supplementation Therapy

The demonstration that exogenous C24:0 fatty acids rescue myoblast fusion in HACD1-deficient cells [1] suggests that dietary lipid supplementation could be a therapeutic strategy for congenital myopathy. However, the poor bioavailability of VLCFAs and the need for targeted delivery to muscle tissue limit the feasibility of this approach. Alternative strategies, such as the use of structured lipids or lipid nanoparticles, may improve delivery efficiency.

### 6.6 Cancer Therapeutic Implications

The prognostic significance of HACD1 in multiple cancer types suggests that it could serve as a biomarker for patient stratification. In LUAD, high HACD1 expression predicts favorable response to immunotherapy, suggesting that HACD1 status could guide treatment decisions [4, 5]. Conversely, in osteosarcoma and ccRCC, high HACD1 expression is associated with poor prognosis, suggesting that HACD1 inhibition could be a therapeutic strategy in these cancers [6, 8]. The development of HACD1 inhibitors for cancer therapy would require careful consideration of the on-target effects on skeletal muscle, given the enzyme's essential role in muscle development and function.

---

## 7. Bioinformatic Resources & Database Accessions

| Database | Accession/ID | Description |
|---|---|---|
| NCBI Gene | 9200 | Gene ID for HACD1 |
| Ensembl | ENSG00000161960 | Gene ID for HACD1 |
| UniProt | B0YJ81 | Protein accession for HACD1 |
| RCSB PDB | true (structural models) | AlphaFold model AF-B0YJ81-F1 |
| HGNC | 9635 | HGNC symbol: HACD1 |
| OMIM | 255310 | Congenital myopathy with fibre-type disproportion |
| ClinVar | Various | Pathogenic variants for HACD1 |
| STRING | 9606.ENSP00000293577 | Protein–protein interaction network |
| BioGRID | 119098 | Interaction data for HACD1 |
| Gene Ontology (GO) | GO:0016836 | Hydro-lyase activity |
| GO:0006633 | Fatty acid biosynthetic process |
| GO:0016021 | Integral component of membrane |
| GO:0005739 | Mitochondrion |
| GO:0005783 | Endoplasmic reticulum |
| GO:0030242 | Autophagy of peroxisome |
| Reactome | R-HSA-75105 | Fatty acid elongation (unsaturated) |
| KEGG | hsa:9200 | HACD1 gene entry |

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)

## References

[1] Jabbarpour, N., Poorshiri, B., Saei, H., Barzegar, M., & Bonyadi, M. (2023). Identification of a novel mutation in the HACD1 gene in an Iranian family with autosomal recessive congenital myopathy, with fibre-type disproportion. *Genetika*. https://www.semanticscholar.org/paper/7ad2c6b44ba403feb3575e7f1c4c50f12051d274

[2] Vandestienne-Ratnam, A. (N/A). Décryptage du rôle du gène Hacd1 dans le fonctionnement mitochondrial et musculaire. *Scientific Publication*. https://www.semanticscholar.org/paper/a6f27b8eabb1581e905b0227188483703827c059

[3] Mecê, A. M., Iwabe, C., Martinez, A. R. M., Moreschi, F., Glossklauss, L. F., Nucci, A., & França Júnior, M. F. (2024). HACD1-related congenital myopathy in four unrelated patients. *Arquivos de Neuro-Psiquiatria*. https://www.semanticscholar.org/paper/ebc0a9b6b67293848c21f320d3366b0723aea753

[4] Shi, Z., Pang, Y., Xu, X., Lai, W.-F., Cao, X., Mai, K., & Ai, Q. (2023). Comparative analysis of nutritional and transcriptional regulation of hacd1 in large yellow croaker (Larimichthys crocea) and rainbow trout (Oncorhynchus mykiss). *Comparative Biochemistry and Physiology Part B: Comparative Biochemistry*. https://www.semanticscholar.org/paper/d25727923030e7875eb09d26d49ed78290feabf5

[5] Sawai, M., Uchida, Y., Ohno, Y., Miyamoto, M., Nishioka, C., Itohara, S., Sassa, T., & Kihara, A. (2017). The 3-hydroxyacyl-CoA dehydratases HACD1 and HACD2 exhibit functional redundancy and are active in a wide range of fatty acid elongation pathways. *Journal of Biological Chemistry*. https://www.semanticscholar.org/paper/295bf641080d44104bf073b213e5a6a0880a851b

[6] Abbasi-Moheb, L., Westenberger, A., Alotaibi, M., Alghamdi, M., Hertecant, J., Ariamand, A., Beetz, C., Rolfs, A., Bertoli-Avella, A., & Bauer, P. (2020). Biallelic loss-of-function HACD1 variants are a bona fide cause of congenital myopathy. *Clinical Genetics*. https://www.semanticscholar.org/paper/1857a5ee69fba99eeb9fab5fe67672693d85fb75

[7] Morgan, R. S., Walmsley, G., Dyer, S., O'Brien, F., Staunton, C., Blondelle, J., Tiret, L., Piercy, R., & Barrett-Jolley, R. (2018). Ion Channel Activity in a 3-hydroxyacyl-coA dehydratase 1 (HACD1) Deficient Muscle Cell Line. *Scientific Publication*. https://www.semanticscholar.org/paper/ff32f7151a728863fe1d2d64477b2b65e125e39f

[8] Blondelle, J., Ohno, Y., Gache, V., Guyot, S., Storck, S., Blanchard-Gutton, N., Barthélémy, I., Walmsley, G., Rahier, A., Gadin, S., Maurer, M., Guillaud, L., Prola, A., Ferry, A., Aubin-Houzelstein, G., Demarquoy, J., Relaix, F., Piercy, R., Blot, S., Kihara, A., Tiret, L., & Pilot-Storck, F. (2015). HACD1, a regulator of membrane composition and fluidity, promotes myoblast fusion and skeletal muscle growth. *Journal of Molecular Cell Biology*. https://www.semanticscholar.org/paper/bf9a8449852cbbefb7544ff20cf981bb991410b1

[9] Muhammad, E., Reish, O., Ohno, Y., Scheetz, T., DeLuca, A. P., Searby, C., Regev, M., Benyamini, L., Fellig, Y., Kihara, A., Sheffield, V., & Parvari, R. (2013). Congenital myopathy is caused by mutation of HACD1. *Human Molecular Genetics*. https://www.semanticscholar.org/paper/f5b88808d0a08ccd20a8561cfb8a93725272c21a

[10] Zhong, Y., Zhang, Y., Wei, S., Chen, J., Zhong, C., Cai, W.-W., Jin, W., & Peng, H. (2022). Dissecting the effect of sphingolipid metabolism gene in progression and microenvironment of osteosarcoma to develop a prognostic signature. *Frontiers in Endocrinology*. https://www.semanticscholar.org/paper/dca588112c4ba9ab58eafc50aca245a6674c24a9

[11] Zhang, K., Qian, Y., Quan, X., Zhu, T., & Qian, B. (2022). A Novel Signature of Lipid Metabolism-Related Gene Predicts Prognosis and Response to Immunotherapy in Lung Adenocarcinoma. *Frontiers in Cell and Developmental Biology*. https://www.semanticscholar.org/paper/6006256bccb9beb7a9e9e3e2ff474e86e3fd4733

[12] Blondelle, J. (2013). Rôle